https://www.pharmaradar360.com/article/e8d6058a003a706cPharmaRadar360en2026-05-09T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/8efd6b595b99ab3ePharmaRadar360en2026-05-09T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/f2b7b489a722d557PharmaRadar360en2026-05-09T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/1ae5ce368ab99aedPharmaRadar360en2026-05-09T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/8d2818b96695b7f7PharmaRadar360en2026-05-09T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/7f996eb2e722f94cPharmaRadar360en2026-05-09T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/35e10c6ba0790079PharmaRadar360en2026-05-09T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/d100ebc02c8e8c02PharmaRadar360en2026-05-09T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/e4ba183c2bcd3920PharmaRadar360en2026-05-09T00:00:00.000Zlegal update regarding risdiplamhttps://www.pharmaradar360.com/article/54e153e6ddd82033PharmaRadar360en2026-05-09T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/59d85477478348d5PharmaRadar360en2026-05-09T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/e4259d689c90702cPharmaRadar360en2026-05-09T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/c203f93529f3968cPharmaRadar360en2026-05-09T00:00:00.000Z6203https://www.pharmaradar360.com/article/e3640ebff3a35b4cPharmaRadar360en2026-05-09T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/05312d388cdba2eePharmaRadar360en2026-05-08T21:58:01.000ZJournal of Clinical Oncology: Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase 1/1b Trialhttps://www.pharmaradar360.com/article/aa4ccea105871c0cPharmaRadar360en2026-05-08T17:30:00.000Z当社に対する訴訟の提起に関するお知らせhttps://www.pharmaradar360.com/article/fc3c00e4ede711f4PharmaRadar360en2026-05-08T15:08:39.000ZStrategic Capital Supports Pivotal-Stage Executionhttps://www.pharmaradar360.com/article/50a3596be3cd3129PharmaRadar360en2026-05-08T14:49:03.000ZAspen Group Chief Operations Officer highlights Aspen’s role at the World Bank & IMF spring meetingshttps://www.pharmaradar360.com/article/d9ec32b6e8654f2aPharmaRadar360en2026-05-08T13:23:52.000ZZymeworks to Present at Respiratory Innovation Summithttps://www.pharmaradar360.com/article/fcbdebfb59144339PharmaRadar360en2026-05-08T12:23:52.000ZDecision: Marketing authorisations Granted in 2026https://www.pharmaradar360.com/article/7cc416811dd77d32PharmaRadar360en2026-05-08T12:23:04.000ZDecision: Parallel import licences granted in 2026https://www.pharmaradar360.com/article/43cb973088087257PharmaRadar360en2026-05-08T12:12:22.000ZLa AEMPS informa del cese de comercialización, retirada y recuperación de los cosméticos Inoar G.Hair 2 Anti-Volume Treatment e Inoar Moroccan Step 2 Capilary Treatmenthttps://www.pharmaradar360.com/article/5d22672b716a9b59PharmaRadar360en2026-05-08T11:51:24.000ZCorporate report: Advertising investigations: April 2026https://www.pharmaradar360.com/article/abd011488276a81bPharmaRadar360en2026-05-08T11:46:52.000ZΑΝΑΡΤΗΣΗ ΛΙΣΤΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΣΚΕΥΑΣΜΑΤΩΝ ΠΕΡΙΟΡΙΣΜΕΝΗΣ ΔΙΑΘΕΣΙΜΟΤΗΤΑΣ 30 ΑΠΡΙΛΙΟΥ 2026https://www.pharmaradar360.com/article/ec9b9b7cb53bef0cPharmaRadar360en2026-05-08T10:59:00.000ZBristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adultshttps://www.pharmaradar360.com/article/5d11e59f909a6f6aPharmaRadar360en2026-05-08T10:30:23.000ZMerck Statement on Daiichi Sankyo Update to Manufacturing and Supply Planhttps://www.pharmaradar360.com/article/1830780ebaff6633PharmaRadar360en2026-05-08T09:00:00.000Zはしる図書館「日本新薬きらきら未来ゴー！」（2025年度 活動報告）https://www.pharmaradar360.com/article/bf02661fb4978199PharmaRadar360en2026-05-08T00:00:00.000ZHow Much Water Should You Drink in a Day?https://www.pharmaradar360.com/article/6fa82f108a18256cPharmaRadar360en2026-05-07T23:01:51.000ZImproved early warning systems needed to reduce medicines supply risks, says ABPI